Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Avadel Pharmaceuticals in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings per share of ($0.04) for the quarter. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals' Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.11 EPS, FY2026 earnings at $0.65 EPS and FY2029 earnings at $1.90 EPS.
A number of other analysts also recently issued reports on AVDL. Needham & Company LLC reissued a "buy" rating and set a $19.00 target price on shares of Avadel Pharmaceuticals in a research report on Wednesday, April 9th. HC Wainwright reissued a "buy" rating and set a $21.00 price target on shares of Avadel Pharmaceuticals in a research report on Tuesday, March 4th. Piper Sandler lowered their price objective on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $12.00 price target on the stock. Finally, UBS Group dropped their price objective on Avadel Pharmaceuticals from $22.00 to $14.00 and set a "buy" rating on the stock in a report on Monday, January 13th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $19.88.
Read Our Latest Analysis on Avadel Pharmaceuticals
Avadel Pharmaceuticals Stock Down 1.5 %
Shares of NASDAQ AVDL traded down $0.12 during trading on Tuesday, hitting $8.03. 1,099,648 shares of the company traded hands, compared to its average volume of 1,220,433. The company has a 50-day moving average price of $7.97 and a 200-day moving average price of $9.93. Avadel Pharmaceuticals has a 1 year low of $6.38 and a 1 year high of $19.09. The firm has a market capitalization of $775.93 million, a P/E ratio of -10.16 and a beta of 1.52.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in AVDL. FMR LLC acquired a new position in Avadel Pharmaceuticals during the 3rd quarter worth approximately $31,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Avadel Pharmaceuticals during the 3rd quarter valued at about $484,000. State Street Corp boosted its stake in Avadel Pharmaceuticals by 42.5% during the third quarter. State Street Corp now owns 1,623,302 shares of the company's stock worth $21,290,000 after acquiring an additional 483,787 shares in the last quarter. Wellington Management Group LLP acquired a new position in Avadel Pharmaceuticals during the 3rd quarter worth approximately $633,000. Finally, MML Investors Services LLC boosted its holdings in Avadel Pharmaceuticals by 13.8% in the third quarter. MML Investors Services LLC now owns 136,356 shares of the company's stock worth $1,788,000 after acquiring an additional 16,500 shares in the last quarter. 69.19% of the stock is owned by institutional investors.
Insider Buying and Selling at Avadel Pharmaceuticals
In related news, Director Linda Palczuk acquired 5,000 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were bought at an average cost of $7.93 per share, with a total value of $39,650.00. Following the completion of the transaction, the director now directly owns 67,900 shares of the company's stock, valued at $538,447. This trade represents a 7.95 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 4.80% of the company's stock.
About Avadel Pharmaceuticals
(
Get Free Report)
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Featured Articles
Before you consider Avadel Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avadel Pharmaceuticals wasn't on the list.
While Avadel Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
